
Wacker CDMO Arm to Produce CureVac Vaccine
Germany’s Wacker Chemie has signed a contract to manufacture the active substance for compatriot CureVac’s Covid-19 vaccine candidate CVnCoV. Under the terms, the biotech arm of the Munich-based chemical group will ramp up GMP production of the mRNA drug substance for the candidate at its Amsterdam site in the first half of 2021.